Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology (Q34465555)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology (English)

1 reference

Europe PubMed Central

2 August 2017

1 reference

based on heuristic

inferred from title

0 references

Borwin Bandelow

4

1 reference

Europe PubMed Central

2 August 2017

3

object named as

David J Nutt

0 references

object named as

J Scott

10

0 references

Ian M. Anderson

object named as

Ian M Anderson

2

0 references

9

object named as

Martin Knapp

1 reference

Europe PubMed Central

2 August 2017

Hans-Ulrich Wittchen

1 reference

ORCID Public Data File 2021

British Association for Psychopharmacology

12

object named as

British Association for Psychopharmacology

1 reference

Europe PubMed Central

2 August 2017

author name string

David S Baldwin

1

1 reference

Europe PubMed Central

2 August 2017

A Bond

5

1 reference

Europe PubMed Central

2 August 2017

Jonathan R T Davidson

6

1 reference

Europe PubMed Central

2 August 2017

J A den Boer

7

1 reference

Europe PubMed Central

2 August 2017

Naomi A Fineberg

8

1 reference

Europe PubMed Central

2 August 2017

H-U Wittchen

11

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

1 November 2005

1 reference

Europe PubMed Central

2 August 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

2 August 2017

19

1 reference

Europe PubMed Central

2 August 2017

6

1 reference

Europe PubMed Central

2 August 2017

567-596

1 reference

Europe PubMed Central

2 August 2017

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cost of anxiety disorders in Europe.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Obsessive-compulsive syndromes and disorders: significance of comorbidity with bipolar and anxiety syndromes

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

GABA-ergic drugs: exit stage left, enter stage right

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Sexual dysfunction associated with antidepressant drugs

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Evidence-based pharmacotherapy of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Double-blind placebo-controlled pilot study of paroxetine for specific phobia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The validity of the Hospital Anxiety and Depression Scale. An updated literature review

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The evidence-based pharmacological treatment of social anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Treatment of panic disorder via the Internet: a randomized trial of CBT vs. applied relaxation.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Prevalence and development of psychiatric disorders in childhood and adolescence

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Psychoeducation in panic disorder patients: effect of a self-information booklet in a randomized, masked-rater study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Three year naturalistic outcome study of panic disorder patients treated with paroxetine

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Treatment of anxiety and depressive disorders in patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Why is self-help neglected in the treatment of emotional disorders? A meta-analysis.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Size and burden of social phobia in Europe

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Epidemiology and comorbidity of anxiety disorders in the elderly

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Effectiveness and cost of the inpatient treatment of posttraumatic stress disorder: comparison of three models of treatment.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The epidemiology of panic disorder and agoraphobia in Europe

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Physicians' and patients' choices in evidence based practice

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cognitive-behavioral therapy for social anxiety disorder: current status and future directions

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Antidepressants for generalised anxiety disorder (GAD)

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Social phobia subtypes in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Posttraumatic stress disorder in the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A European perspective on social anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Onset of panic disorder with agoraphobia. Toward an integrated model.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Comparison of the General Health Questionnaire and the Hospital Anxiety and Depression Scale.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The epidemiology of generalized anxiety disorder in Europe

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

DSM depression and anxiety criteria and severity of symptoms in primary care: cross sectional study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Death and dependence: current controversies over the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Death by tricyclic: the real antidepressant scandal?

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The placebo response in social phobia

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Recognition, management, and course of anxiety and depression in general practice.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The economic consequences of social phobia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pilot study of secondary prevention of posttraumatic stress disorder with propranolol

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Sertraline treatment of panic disorder: results of a long-term study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Mirtazapine versus fluoxetine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Long-term Therapeutic Use of Benzodiazepines

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Outcome of anxiety and depressive disorders in primary care.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Prospective study of posttraumatic stress disorder and depression following trauma

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Randomized controlled trial of yogic meditation techniques for patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The relative efficacy of buspirone, imipramine and placebo in panic disorder: A preliminary report

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Cost of anxiety disorders: impact of comorbidity.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pharmacotherapy for social phobia

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Social phobia symptoms, subtypes, and severity: findings from a community survey

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Occurrence, recognition, and outcome of psychological disorders in primary care.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Efficacy of self-help manuals for anxiety disorders in primary care: a systematic review

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Social phobia in general health care: an unrecognised undertreated disabling disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Factors predicting the clinical course of generalised anxiety disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

An epidemiological study of obsessive-compulsive disorder and related disorders in Israeli adolescents

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

A Randomized Controlled Trial of Cognitive Therapy, a Self-help Booklet, and Repeated Assessments as Early Interventions for Posttraumatic Stress Disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Treating Medication-Resistant Panic Disorder: Predictors and Outcome of Cognitive-Behavior Therapy in a Brazilian Public Hospital

1 reference

https://api.crossref.org/works/10.1177%2F0269881105059253

21 January 2018

Identifiers

10.1177/0269881105059253

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34465555&oldid=2120093828"